166 patents
Page 5 of 9
Utility
TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS
10 Mar 22
The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins.
Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
Filed: 2 Jul 21
Utility
CTLA4-Ig immunoadhesins
22 Feb 22
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Gregory A. Lazar, Matthew J. Bernett
Filed: 15 Apr 21
Utility
Heterodimeric Antibodies That Bind CD3 and Tumor Antigens
10 Feb 22
The present invention is directed to novel heterodimeric antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 18 Oct 21
Utility
IL-15/IL-15RA Heterodimeric FC Fusion Proteins and Uses Thereof
10 Feb 22
The present invention is directed to novel IL-15/IL-15Rα heterodimeric Fc fusion proteins and uses thereof.
Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Filed: 22 Mar 21
Utility
Bispecific checkpoint inhibitor antibodies
1 Feb 22
The present invention is directed to heterodimeric anti-PD-1 x anti-CTLA-4.
Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
Filed: 7 Jun 19
Utility
Heterodimeric antibodies that bind somatostatin receptor 2
18 Jan 22
The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).
Gregory Moore, Rumana Rashid, Sung-Hyung Lee, Paul Foster
Filed: 24 Apr 19
Utility
Heterodimeric antibodies that bind CD3 and tumor antigens
18 Jan 22
The present invention is directed to novel heterodimeric antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 14 Mar 19
Utility
Methods and Compositions for Inhibiting CD32B Expressing Cells
23 Dec 21
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Filed: 30 Aug 21
Utility
Fc variants with altered binding to FcRn
14 Dec 21
The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
Filed: 20 Sep 17
Utility
Targeted IL-12 Heterodimeric Fc-fusion Proteins
18 Nov 21
The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat, Eric Chang
Filed: 2 Oct 20
Utility
Bispecific Antibodies That Bind to CD38 and CD3
7 Oct 21
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais
Filed: 30 Oct 20
Utility
HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
16 Sep 21
The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
Filed: 12 Oct 20
Utility
Fc VARIANTS WITH ALTERED BINDING TO FcRn
9 Sep 21
The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Filed: 23 Oct 20
Utility
Heterodimeric antibodies that bind CD3 and tumor antigens
7 Sep 21
The present invention is directed to novel heterodimeric antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 4 Apr 18
Utility
Heterodimeric Antibodies That Bind Fibroblast Activation Protein
19 Aug 21
The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
John Desjarlais, Alex Nisthal, Seung Chu
Filed: 16 Apr 21
Utility
Bispecific Immunomodulatory Antibodies That Bind Costimulatory and Checkpoint Receptors
19 Aug 21
The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
Filed: 16 Apr 21
Utility
Modulation of T cells with bispecific antibodies and Fc fusions
17 Aug 21
The present invention relates to methods and compositions for modulating T cells.
Matthew Bernett, Seung Chu, Dilki Wickramarachichi, John Desjarlais
Filed: 8 Mar 19
Utility
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
10 Aug 21
The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins.
Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
Filed: 2 Jul 18
Utility
PD-1 Targeted IL-15/IL-15RALPHA FC Fusion Proteins with Improved Properties
29 Jul 21
The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains.
John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
Filed: 9 Oct 20
Utility
Novel CTLA4-IG Immunoadhesins
29 Jul 21
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Gregory A. Lazar, Matthew J. Bernett
Filed: 15 Apr 21